Prognostication in young and old patients with Waldenström's macroglobulinemia: Importance of the international prognostic scoring system and of serum lactate dehydrogenase

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 50-52

  Kastritis, Efstathios ^a   Zervas, Konstantinos ^a   Repoussis, Panagiotis ^a   Michali, Evridiki ^a   Katodrytou, Eirini ^a   Zomas, Athanasios ^a   Simeonidis, Argiris ^a   Terpos, Evangelos ^a   Delimbassi, Sossana ^a   Vassou, Amalia ^a   Gika, Dimitra ^a   Dimopoulos, Meletios ^a   Myeloma, Greek ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Age; Anemia; Disease specific survival; Hyperviscosity; Waldenstr m

Indexed keywords

ALBUMIN; ALKYLATING AGENT; LACTATE DEHYDROGENASE; NUCLEOSIDE ANALOG; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; DISEASE ACTIVITY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SPLENOMEGALY; WALDENSTROEM MACROGLOBULINEMIA; AGE; BLOOD; ENZYMOLOGY; FEMALE; MALE; MIDDLE AGED; SURVIVAL RATE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649538156     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.012     Document Type: Article

References (12)

1. Gobbi PG, Bettini R, Montecucco C, et al. Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood 1994; 83:2939-45.
2. Morel P, Monconduit M, Jacomy D, et al. patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96:852-8.
3. Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115:575-82.
4. Owen RG, Barrans SL, Richards SJ, et al. Waldenstrom macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 2001; 116:420-8.
5. Dimopoulos MA, Hamilos G, Zervas K, et al. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. Ann Oncol 2003; 14:1299-305.
6. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup tria (SW0G S9003). Semin Oncol 2003; 30:220-5.
7. Merlini G, Baldini L, Broglia C, et al. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:211-5.
8. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133:158-64.
9. Morel P, Duhamel A, Gobbi P, et al. International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM). Blood 2006; 108:42a (Abstract 127).
10. Dimopoulos MA, Barlogie B, Smith TL, et al. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 1991; 115:931-5.
11. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-94.
12. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258-65.